Cargando…

Vaccine Adjuvant Nanotechnologies

The increasing sophistication of vaccine adjuvant design has been driven by improved understanding of the importance of nanoscale features of adjuvants to their immunological function. Newly available advanced nanomanufacturing techniques now allow very precise control of adjuvant particle size, sha...

Descripción completa

Detalles Bibliográficos
Autores principales: Barclay, T., Petrovsky, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151801/
http://dx.doi.org/10.1016/B978-0-323-39981-4.00007-5
_version_ 1783521332995031040
author Barclay, T.
Petrovsky, N.
author_facet Barclay, T.
Petrovsky, N.
author_sort Barclay, T.
collection PubMed
description The increasing sophistication of vaccine adjuvant design has been driven by improved understanding of the importance of nanoscale features of adjuvants to their immunological function. Newly available advanced nanomanufacturing techniques now allow very precise control of adjuvant particle size, shape, texture, and surface chemistry. Novel adjuvant concepts include self-assembling particles and targeted immune delivery. These individual concepts can be combined to create a single integrated vaccine nanoparticle-combining antigen, adjuvants, and DC-targeting elements. In the process, the concept of an adjuvant has broadened to include not only immune-stimulatory substances but also any design features that enhance the immune response against the relevant vaccine antigen. The modern definition of an adjuvant includes not only classical immune stimulators but also any aspects of particle size, shape, and surface chemistry that enhance vaccine immunogenicity. It even includes purely physical processes such as texturing of particle surfaces to maximize immunogenicity. Looking forward, adjuvants will increasingly be seen not as separate add-on items but as wholly integrated elements of a complete vaccine delivery package. Hence, vaccine systems will increasingly approach the complexity and sophistication of pathogens themselves, incorporating highly specific particle properties, contents, and behaviors, all designed to maximize immune system recognition and drive the immune response in the specific direction that affords maximal protection.
format Online
Article
Text
id pubmed-7151801
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-71518012020-04-13 Vaccine Adjuvant Nanotechnologies Barclay, T. Petrovsky, N. Micro and Nanotechnology in Vaccine Development Article The increasing sophistication of vaccine adjuvant design has been driven by improved understanding of the importance of nanoscale features of adjuvants to their immunological function. Newly available advanced nanomanufacturing techniques now allow very precise control of adjuvant particle size, shape, texture, and surface chemistry. Novel adjuvant concepts include self-assembling particles and targeted immune delivery. These individual concepts can be combined to create a single integrated vaccine nanoparticle-combining antigen, adjuvants, and DC-targeting elements. In the process, the concept of an adjuvant has broadened to include not only immune-stimulatory substances but also any design features that enhance the immune response against the relevant vaccine antigen. The modern definition of an adjuvant includes not only classical immune stimulators but also any aspects of particle size, shape, and surface chemistry that enhance vaccine immunogenicity. It even includes purely physical processes such as texturing of particle surfaces to maximize immunogenicity. Looking forward, adjuvants will increasingly be seen not as separate add-on items but as wholly integrated elements of a complete vaccine delivery package. Hence, vaccine systems will increasingly approach the complexity and sophistication of pathogens themselves, incorporating highly specific particle properties, contents, and behaviors, all designed to maximize immune system recognition and drive the immune response in the specific direction that affords maximal protection. 2017 2016-10-07 /pmc/articles/PMC7151801/ http://dx.doi.org/10.1016/B978-0-323-39981-4.00007-5 Text en Copyright © 2017 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Barclay, T.
Petrovsky, N.
Vaccine Adjuvant Nanotechnologies
title Vaccine Adjuvant Nanotechnologies
title_full Vaccine Adjuvant Nanotechnologies
title_fullStr Vaccine Adjuvant Nanotechnologies
title_full_unstemmed Vaccine Adjuvant Nanotechnologies
title_short Vaccine Adjuvant Nanotechnologies
title_sort vaccine adjuvant nanotechnologies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151801/
http://dx.doi.org/10.1016/B978-0-323-39981-4.00007-5
work_keys_str_mv AT barclayt vaccineadjuvantnanotechnologies
AT petrovskyn vaccineadjuvantnanotechnologies